Michael Soler, MD
Family Medicine · Portland, TXNPI 1285901140
Payments from drug & device makers
Across 339 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$569
- AstraZeneca$566
- Lilly USA, LLC$448
- Pfizer$383
- AbbVie$370
- Johnson & Johnson$294
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,93299%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $569 |
| AstraZeneca | 31 | $566 |
| Lilly USA, LLC | 43 | $448 |
| Pfizer | 33 | $383 |
| AbbVie(2 entities) | 24 | $370 |
| Johnson & Johnson | 19 | $294 |
| Amgen | 21 | $268 |
| GSK | 15 | $268 |
| Sanofi-aventis U.S. LLC | 18 | $240 |
| Boehringer Ingelheim | 11 | $199 |
| Merck | 15 | $183 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $166 |
| Mylan Specialty L.p. | 5 | $123 |
| Bayer | 5 | $94 |
| Novartis | 5 | $85 |
| Sumitomo Pharma America, Inc. | 4 | $78 |
| Abbott | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 5 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $56 |
| Ardelyx, Inc. | 2 | $54 |
| Eisai Inc. | 3 | $52 |
| Shire North American Group Inc | 3 | $46 |
| Radius Health, Inc. | 3 | $43 |
| Exact Sciences | 2 | $40 |
| Amarin Pharma, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $28 |
| Dexcom, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $11 |
How this compares
$4,987 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 210 | $243,436 |
| OzempicSemaglutide | 69 | $86,165 |
| Humira PenAdalimumab | 11 | $73,209 |
| JardianceEmpagliflozin | 86 | $67,777 |
| EliquisApixaban | 64 | $59,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $56,926 |
| CreonLipase/Protease/Amylase | 15 | $41,614 |
| XareltoRivaroxaban | 31 | $31,791 |
| TrulicityDulaglutide | 21 | $27,198 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $26,898 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $20,699 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 716 | $18,543 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,408 |
| TradjentaLinagliptin | 12 | $17,233 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $16,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $448 | $270,634231 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Stiolto Respimat, Glyxambi | $199 | $121,517152 claims |
| Novo NordiskOzempic | $569 | $86,16569 claims |
| AbbVieCreon, Linzess, Namzaric, Synthroid | $370 | $62,83770 claims |
| PfizerEliquis | $383 | $59,96964 claims |
| GSKTrelegy Ellipta | $268 | $56,92659 claims |
| Johnson & JohnsonXarelto | $294 | $31,79131 claims |
| MerckJanuvia, Janumet | $183 | $28,27636 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $566 | $25,28357 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $14,58031 claims |
| NovartisEntresto | $85 | $11,64013 claims |
| Sanofi-aventis U.S. LLCMultaq | $240 | $9,15112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Portland
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.